Trade Name (Agent): CMS I-neb
Sponsor: Zambon
Date of BT Designation Disclosure: 4/21/2022
Indication: Treatment for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB) colonized with P. aeruginosa.
Category: Other